Overview

Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
AZD-3199
Formoterol Fumarate